Pfizer inks $2.3 B CAR-T deal with China's Starna Therapeutics
Singapore, Nov. 19 -- Pfizer Inc. has entered into an exclusive licensing agreement with China-based Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialise three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programmes that are focused on treating autoimmune diseases.
Pfizer also receives rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive right...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.